Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to Eclair's Therapeutics first quarter 2023 conference call. At this time, all participants are in a listen-only mode. To ask, there'll be a question and answer session. To ask a question, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To remove yourself from the queue, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Robert Doody, Head of Investor Relations. Please go ahead. Thank you. I am Robert Doody, Head of Investor Relations for Eclaris. Please note that earlier today we issued a press release highlighting our first quarter 2023 financial results and other business matters. For those of you who have not yet seen it, you will find the press release posted under the Press Releases page of the Investors section of our website www.eclaristx.com. In addition, we will be referring to a slide deck entitled Q1 2023 Investor Conference Call, which can be found on the investor page of our corporate website and furnished as an exhibit to our Form 8K that we filed with the SEC earlier this morning. Joining me today for the call are Doug Mannion, our Chief Executive Officer, Gail Caulkwell, our Chief Medical Officer, Joe Monahan, our Chief Scientific Officer, and Kevin Balthaser, our Chief Financial Officer. Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the company's future results of operations and financial position, business strategy, and plans and objectives for Eclaris future operations are considered forward-looking statements within the meaning of federal securities law...